It has been brought to the publisher's attention, that there was an error in Table 1 of the above article, published in TH Open , Volume 3, Number 3, 2019, pages e309–e315 (DOI: 10.1055/s-0039-1696659 ). In the SELECT-D study, it should state “ N = 406” instead of “ N = 203”.
The correct table appears below.
Table 1. Protocol design of randomized control trials on anticoagulants for the treatment of cancer-associated thrombosis.
| Study (year) | Study drug/comparator | Patients | Methods/statistics | Primary endpoint | Secondary endpoints | Duration (mo) |
|---|---|---|---|---|---|---|
|
ONCENOX
39
N = 122 (2006) |
Enoxaparin/warfarin | Active cancer, acute symptomatic VTE | Pilot feasibility | VTE recurrence | Major and minor bleeding | 6 |
|
CANTHANOX
25
N = 146 (2002) |
Enoxaparin/warfarin | Active or treated cancer, PE, and/or DVT | S | Composite of major bleeding or recurrent VTE | Recurrent VTE Major bleeding |
3 |
|
CLOT
26
N = 672 (2003) |
Dalteparin/warfarin | Active cancers, acute proximal symptomatic DVT or PE | Phase III/S | Symptomatic recurrence of DVT, PE, or both | Major bleeding Any bleeding |
6 |
|
LITE CANCER
27
N = 200 (2006) |
Tinzaparin/warfarin | Cancer, acute proximal DVT | Phase III/S | Recurrent VTE or death | Major and minor bleeding | 3 |
|
CATCH
22
N = 900 (2015) |
Tinzaparin/warfarin | Active cancers, acute proximal symptomatic DVT or PE | Phase III/S | VTE recurrence: proximal DVT, PE either symptomatic or incidental | Major bleeding CRNMB |
6 |
|
SELECT-D
23
N = 406 (2018) |
Rivaroxaban/dalteparin | All active cancers, proximal DVT, PE, incidental PE | Pilot | VTE recurrence: proximal DVT, PE either symptomatic or incidental, and other sites | Major bleeding CRNMB |
6 |
|
HOKUSAI-VTE Cancer
21
N = 1,046 (2018) |
Edoxaban/dalteparin | Active or history of cancer, acute symptomatic or incidental VTE | Phase III/NI | Composite of VTE recurrence (symptomatic or incidental) or major bleeding | VTE recurrence Major bleeding CRNMB |
12 |
|
CARAVAGGIO
35
N = 1,168 (2019) |
Apixaban/dalteparin | Active or history of cancer, symptomatic or incidental proximal DVT or PE | Phase III/NI | Symptomatic or incidental VTE recurrence | Major bleeding | 6 |
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; DVT, deep-vein thrombosis; NI, noninferiority trial; PE, pulmonary embolism; S, superiority trial; VTE, venous thromboembolism.